

ASX Announcement

25th July 2024

COMPLETION OF \$1.0M CAPITAL RAISING & CLEANSING NOTICE

25 July 2024 – Medical technology company Singular Health Group Ltd (ASX: SHG) (“Singular Health”, or “the Company”) is pleased to announce it has completed the \$1.0M capital raising from Craig Sellars previously announced on 14 March 2024 and approved by shareholders on 27 June 2024.

The Company confirms it has raised \$1.0M from Craig Sellars, via the issue of 6,666,667 fully paid ordinary shares (“Shares”) at \$0.15 per share (“Placement”).

In addition to the above, the Company has issued the following securities:

- 336,364 fully paid ordinary shares to Director Andrew Just in lieu of cash payment of Director fees, approved by shareholders on 27 June 2024;
- 378,218 fully paid ordinary shares to Director Howard Digby in lieu of cash payment of Director fees, approved by shareholders on 27 June 2024
- 1,000,000 fully paid ordinary shares to Nigel Brown, approved by shareholders on 27 June 2024; and
- 2,775,000 fully paid ordinary shares to Singular Health employees, pursuant to the terms of the Company’s Employee Incentive Plan. The shares were issued under Exception 9 of ASX Listing Rule 7.2, and upon the exercise of vested performance rights following the achievement of respective vesting conditions.

Furthermore, the Company has issued the following unlisted securities:

- 8,500,000 unlisted options (exercisable at \$0.15 and expiring 3 years from issue) to Shaw and Partners Limited (or their nominee/s), approved by shareholders on 27 June 2024, and
- 10,000,000 Performance Rights to Mr Denning Chong, subject to vesting conditions, approved by shareholders on 27 June 2024.

Refer to the Notice of Meeting dated 21 May 2024 for further details in respect of the above allotments.

Notice pursuant to Section 708A(5)(e) of the Corporations Act 2001

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) ("**Corporations Act**") that:

1. the Company on 25 July 2024 issued 11,156,249 Shares without disclosure to investors under Part 6D.2 of the Corporations Act;
2. the Company is providing this notice under section 708A(5)(e) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
 - a. the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. sections 674 and 674A of the Corporations Act; and
4. as at the date of this notice, there is no "excluded information" within the meaning of sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by the Company.

Please refer to the ASX announcements dated 14 March 2024, 21 May 2024, 17 June 2024 and the accompanying Appendix 2A and Appendix 3G for further details.

This announcement is authorised for release by the Board of Directors of the Company.

Ends

For further information contact

Investors	Corporate
James Hill +61 413 825 646 jhill@singular.health	Steven Wood Company Secretary support@singular.health

About Singular Health:

Singular Health Group Limited (ASX: SHG) is a medical technology company utilising advanced technologies to develop patient-specific solutions.

Singular Health’s 3Dicom software solutions empower patients and practitioners to better visualise, communicate, and understand medical imaging data. 3Dicom MD® is cleared for diagnostic use in the United States.

Singular 3DP, a wholly owned subsidiary of Singular Health, uses advanced manufacturing including 3D printing and post-processing to manufacture TGA-approved patient-specific medical devices.

To learn more, visit: <https://www.singular.health> and <https://investors.singular.health/>